Global Blood Therapeutics, Inc. (GBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

32.80

+0.85

(+2.66%)

At close: 04:00PM EDT

33.00

+0.20

(+0.61%)

After hours:

04:08PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	31.95
Open	32.04
Bid	26.08 x 3200
Ask	34.00 x 1200
Day's Range	31.58 - 33.76
52 Week Range	21.65 - 40.69
Volume	1,247,896
Avg. Volume	1,531,629

Market Cap	2.135B
Beta (5Y Monthly)	1.11
PE Ratio (TTM)	N/A
EPS (TTM)	-4.86
Earnings Date	Aug 01, 2022 - Aug 05, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	59.68

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GBT

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Global Blood Therapeutics, Inc.
Technical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.
Rating
Fair Value
Economic Moat
4 days agoArgus Research

All

Zacks
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the trial
Motley Fool
Why Global Blood Therapeutics Trended Upward Today
Global Blood Therapeutics' (NASDAQ: GBT) stock rose by more than 8.2% on Wednesday as of 2:40 p.m. ET on news that the company initiated a phase 2/3 clinical trial for its candidate called GBT601, which is being developed to treat sickle cell disease. The trial will be the biotech's fourth ongoing late-stage sickle cell disease therapy project, not to mention a trio of earlier-stage projects for the same indication. Global Blood Therapeutics already has one medicine approved to treat sickle cell disease called Voxelotor.
GlobeNewswire
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trialSOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company’s investigational next-generation sickle hemoglobin (HbS) polymerization inhibitor. The study (NCT05431088) is a randomized, multicenter Phase 2/3 clinical trial evaluat
- Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
  PR Newswire
- Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
  PR Newswire